The efficacy of early HA-330 hemoperfusion for severe and critical COVID-19 patients in a tertiary hospital : A randomized control trial

Phase 2

Completed

• Conditions: COVID-19 patients (Severe and critical); Early hemoperfusion , Severe and critical COVID-19

• Registration Number: TCTR20211102004
• Lead Sponsor: /A

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-11-02
• Study Completion: 2022-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. COVID-19 patients with age more than 15 year
2. Diagnosed as severe or critical COVID-19 infection
3. Already received favipirair or remdesivir in combination with corticosteroid (more than 6 mg of dexamethasone or equivalent dose) for more than 24-48 hours
4. Hyperinflammatory state including CRP > 75 mg/L , ferritin > 300 ng/ml and serum IL-6 level > 20 pg/ml
5. Hypoxemia with PaO2 / FiO2 < 300 and/or oxygen saturation room air < 92 percent and/or Lung infiltration increasing more than 50 percent within 24-48 hours

Exclusion Criteria

1. Patients in terminal states (estimated no more than 24 hours alive)
2. Pregnancy
3. History of HA-330 catridge or Tocilizumab allergy
4. Recent myocardial infarction within 1 month
5. Persistent shock more than 12 hours
6. Patients who accepted DNR (do not resuscitation)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
mortality 28 day 28 day mortality

Secondary Outcome Measures

Name	Time	Method
Ventilator day 28 day Ventilator free day